Last week, Theratechnologies Inc. began marketing a new medicine called tesamorelin (Egrifta)—licensed for the treatment of excess belly fat in some HIV-positive people. Tesamorelin causes the body to produce growth hormone and, as a result, most tesamorelin users can lose some degree of belly fat.
CATIE News – Tesamorelin (Egrifta) comes to Canada – what you need to know
Posted On: Sunday, June 28th, 2015